[Effects of salvianolic acid B and diammonium glycyrrhizinate on portal pressure in rats].
OBJECTIVE
To study the relaxant effects of glycyrrhizinate and salvianolic acid B on rat portal vein in vitro.


METHODS
Healthy female Wistar rats were canalized from hepatic artery, portal vein and hepatic vein in vitro. Remained blood in liver was eliminated with heparinized Krebs-Henseleit solution through hepatic artery, then the liver was isolated under infusing manner. Being constricted with phenylephrine and relaxed with acetylcholine, and infused with glycyrrhizinate or salvianolic acid B, the portal pressures of infused rat livers were consistently monitored by BL-420S physiological experiment system. The median effective concentration (EC50) of the two agents were analyzed with non-linear various slope regression using Prism-4 software.


RESULTS
EC50 of glycyrrhizinate in relaxing the phenylephrine-contracted portal was 1.5556 x 10(-9) mol/L, suggesting one of the mechanism of action of diammonium glycyrhizinate for the treatment of portal hypertension was direct relaxation. Salvianolic acid B showed constrictive action on the phenylephrine-retracted portal vein, the EC50 was 1.4639 x 10(-9) mol/L, indicating that its indirect control action was took part in the portal hypertension therapy synergistically.


CONCLUSIONS
Under the mode with both controlled-velocity and monitored pressure, glycyrrhizinate showed relaxation and salvianolic acid B showed constriction on portal pressure in vitro.
Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing. dycai@implad.ac.cn
Hang
H
Zhou
Si-Xuan
SX
Wang
Tao
T
Zhang
D000818:Animals; D001572:Benzofurans / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D019695:Glycyrrhizic Acid / Q000494:pharmacology*; D006975:Hypertension, Portal / Q000503:physiopathology; D010656:Phenylephrine / Q000494:pharmacology; D011169:Portal Vein / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology; D014666:Vasomotor System / Q000187:drug effects*; D053630:Depsides
D001572:Benzofurans; D019695:Glycyrrhizic Acid; D010656:Phenylephrine; D014662:Vasoconstrictor Agents; D014665:Vasodilator Agents; C076944:salvianolic acid B; D053630:Depsides